ANO1 and bladder transitional cell carcinoma: ANO1 amplified in >35% EC (esophageal carcinoma, ESCA), >6% GC (stomach adenocarcinoma, STAD), and >5% cholangiocarcinoma, and also frequently amplified in other non‐GI cancers, including head and neck squamous cell carcinoma, lung squamous cell carcinoma, breast invasive carcinoma, and bladder urothelial carcinoma (Figure S2A, Supporting Information).